Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector




















Sort by: Date|Relevance

Medigene, Memphasys, Qiagen - which stocks belong in the portfolio?

In times of price fluctuations, so-called 'buy on dips' strategy can be an effective method of achieving a favorable entry price for listed companies. Global trends as a framework can be decisive for a successful investment decision. For a modern society, the healthcare sector...

XPhyto: The Cutting Edge of Medical Cannabis Science

At the forefront of the next wave of cannabis commercialization, is a German-focused company with headquarters in Vancouver, XPhyto Therapeutics Corp. (CSE: XPHY; FSE: 4XT) , that is building a much-coveted cannabis R&D cultivation facility in a converted nuclear bunker and o...

XPhyto Announces a PCR Testing Breakthrough

It’s the technological breakthrough that the world has been waiting for. A small Canadian life sciences company, XPhyto Therapeutics Corp. ( CSE:XPHY ) (FSE:4XT), has just announced its ability to significantly speed up testing for COVID-19 in an...

Shares Rise as The Medicines Company Reports Positive Topline Results...

Shares Rise as The Medicines Company Reports Positive Topline Results from Two Phase 3 Cholesterol Trials The Medicines Company's shares are trading 8.5% higher today after the firm reported positive results from two phase 3 studies for inclisiran, one for familial hype...

Vir Partners with Samsung Biologics on Large-Scale Manufacture of COVID-19 Antibody Treatment

Vir Biotechnology reported it has entered into an agreement with Samsung Biologics valued at $362 million for large-scale manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment. Though U.S. markets are closed for the Good Friday holiday, Samsung Biologics shar...

Valeo Pharma, CureVac, Moderna, Sartorius: high-flyers or latecomers?

The pandemic continues to spread: Germany is now facing a complete lockdown. Meanwhile, there is good news from the vaccine and drug manufacturers. There are several vaccines available, and from 2021 onwards, vaccination programs are to be implemented rapidly in all industrial...

Aurora, Bayer, XPhyto - scalable growth markets with potential

Health is the most precious good in the life of a human being. The preservation and improvement of the quality of life is a large business area. Investors around the globe have the opportunity to participate in many different areas of research and development of products and t...

Buzz on the Bullboards: Cannabis Tops Health Care

(Image via HEXO Corp.) How high can we get? This past week, it has been the question on the minds of traders, when a market roller coaster saw indexes hit record highs while company earnings saw major names soar and fall in equal measure. Tapping into the larges...

XPhyto Therapeutics: Are they Selling the Solution to Germany’s Rapid Testing Crisis?

The Germans call it COVID-19 “rapid testing mania”. But like most manias, it has opened up a Pandora’s box of problems. As the speed of the vaccine rollout program falters in Europe, on-the-spot antigen testing continues to be the ...

Cannabis tester FluroTech is a market disruptor

The legalization of cannabis in Canada - only the second country after Uruguay to do so - presents a huge business opportunity here and elsewhere. The global cannabis market is expected to hit $146 billion by the end of 2025. Most of the action is expected to be centered in ...
1 2 3 4 5 6 7 8 9 10 ...